RESUMEN
The promising role of thiazolidin-4-ones (TZOs) against inflammatory conditions has been reported. From our lab, one of the TZO derivatives, compound 4C, exerted anti-inflammatory potential via inhibition of locally released cytokines and prostaglandin. In continuance, a detailed study was undertaken for the preclinical profiling of this promising TZO derivative against polyarthritis in rats, along with assessment of risk associated with the treatment. Male Sprague-Dawley rats were used for the adjuvant-induced arthritis (AIA) model. Based on the development of secondary lesion, the animals were randomized into different treatment groups. To establish the efficacy of the test compound, parameters such as inflammation, pain, disease progression, cytokines and prostaglandin (PG)-E2 levels and complete blood cell profile were recorded along with radiological and histological examinations of joints. The study also focused on evaluating the side effect of test compound on gastric, liver, renal, blood and cardiovascular components. Compound 4C exerted promising therapeutic effect against secondary lesions in polyarthritis in rats. It limited the progression of chronic inflammation and associated pain in rats. Modulation of cytokine signalling and arachidonate metabolism by 4C was evident from inhibition of interleukin (IL)-6, tumor necrosis factor (TNF)-α and PGE2 generation in AIA rats. Comparatively, compound 4C was safer than diclofenac to cause gastric, liver, renal, blood and cardiovascular toxicities. These finding supports the efficacy and safety profile of 4C, a TZO derivative in limiting the progression of arthritis when administered orally.
Asunto(s)
Analgésicos/uso terapéutico , Antiinflamatorios/uso terapéutico , Artritis Experimental/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Dolor/tratamiento farmacológico , Tiazolidinas/uso terapéutico , Analgésicos/farmacología , Animales , Antiinflamatorios/farmacología , Artritis Experimental/diagnóstico por imagen , Artritis Experimental/metabolismo , Artritis Experimental/patología , Artritis Reumatoide/diagnóstico por imagen , Artritis Reumatoide/metabolismo , Artritis Reumatoide/patología , Presión Sanguínea/efectos de los fármacos , Dinoprostona/metabolismo , Articulaciones del Pie/diagnóstico por imagen , Articulaciones del Pie/efectos de los fármacos , Articulaciones del Pie/patología , Mucosa Gástrica/anatomía & histología , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/metabolismo , Calor , Hiperalgesia/diagnóstico por imagen , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/metabolismo , Hiperalgesia/patología , Interleucina-6/metabolismo , Masculino , Dolor/diagnóstico por imagen , Dolor/metabolismo , Dolor/patología , Radiografía , Ratas Sprague-Dawley , Tiazolidinas/farmacología , Tacto , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
We synthesized twenty thiazolidin-4-one derivatives, which were then characterized by standard chromatographic and spectroscopic methods. From the in vitro glucose uptake assay, two compounds behaved as insulin sensitizers, where they enhanced glucose uptake in isolated rat diaphragm. In high-carbohydrate diet-induced insulin resistant mice, these two thiazolidin-4-ones attenuated hyperglycemia, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia, and glucose intolerance. They raised the plasma leptin but did not reverse the diabetes-induced hypoadiponectinemia. Additionally, compound 3a reduced adiposity. The test compounds were also able to reverse the disturbed liver antioxidant milieu. To conclude, these two novel thiazolidin-4-ones modulated multiple mechanisms involved in metabolic disorders, reversing insulin resistance and thus preventing the development of type-2 diabetes.
Asunto(s)
Ácido 2,4-Diclorofenoxiacético/análogos & derivados , Trastornos del Metabolismo de la Glucosa/tratamiento farmacológico , Resistencia a la Insulina , Tiazolidinas/química , Ácido 2,4-Diclorofenoxiacético/administración & dosificación , Ácido 2,4-Diclorofenoxiacético/síntesis química , Ácido 2,4-Diclorofenoxiacético/química , Animales , Antioxidantes/metabolismo , Glucemia/efectos de los fármacos , Glucemia/metabolismo , Ácido Clofíbrico/administración & dosificación , Ácido Clofíbrico/síntesis química , Ácido Clofíbrico/química , Trastornos del Metabolismo de la Glucosa/sangre , Trastornos del Metabolismo de la Glucosa/patología , Humanos , Insulina/sangre , Leptina/sangre , Hígado/efectos de los fármacos , Hígado/metabolismo , Ratones , Ratas , Tiazolidinas/administración & dosificación , Tiazolidinas/síntesis químicaRESUMEN
Three thiazolidin-4-one derivatives were synthesized, purified and characterized by chromatographic and spectroscopic methods. In the in vitro assays, these compounds inhibited reactive oxygen species (ROS), nitrite and cytokine generation in RAW 264.7 murine macrophages and whole blood. These derivatives attenuated carrageenan-induced acute inflammation in rats. The most effective compound 4C possessed identical anti-inflammatory action at two doses (50 and 100 mg/kg). Further, the effect of compound 4C on locally induced inflammatory mediators was investigated in carrageenan-induced air pouch inflammation in rats. In this model, compound 4C inhibited the cytokines, tumor necrosis factor (TNF)-α and interleukin (IL)-6 (systemic and local). Additionally, compound 4C was able to reduce locally elevated prostaglandin-E2 (PGE2). Inhibition of leukocyte infiltration by compound 4C was correlated with reduced locally released myeloperoxidase (MPO). To conclude, compound 4C corrected the inflammatory condition by negative effect on cytokine (TNF-α, IL-6) network and prostaglandin-E2 generation.